N/A N=1 Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia
Refractory Ventricular Tachycardia
Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=89 A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy
Small Fiber Neuropathy
Primary: Change in Weekly Average of Daily Pain Intensity on the 11 Point NRS — -2.018; -0.933 units on a scale — p=<0.0001
N/A N=47 A Trauma-Informed Approach for Positive Youth Development for Montana Students
Depression, Anxiety · Suicidal Ideation · Stress
Primary: Change in Salivary Cortisol Levels — -0.26; -0.17 ug/dl
Phase 3 N=140 A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel to Correct Infraorbital Hollowing
Infraorbital Hollowing
Primary: Percentage of Participants With at Least a 1-point Improvement Change From Baseline on the Allergan Infraorbital Hollows Scale (AIHS) Based on Evaluating Investigator's…
N/A N=21 Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia
Primary: Number of Adverse Events Reported — 7 adverse events
Phase 4 N=27 Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in SCI
Spinal Cord Injuries · Neuropathic Pain
Primary: Neuropathic Pain — 13.3; 15.6 units on a scale — p=0.67
Phase 1 N=18 Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003)
Cytomegalovirus Infections
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event (AE) — 100.0; 83.3; 0.0; 33.3 Percentage of participants
Phase 4 N=83 Effects of Intranasal Oxytocin on Cigarette Smoking
Nicotine Dependence · Tobacco Smoking
Primary: Smoking Lapse Analogue Task (Delay Score) — 11.5; 10.9 minutes
Phase 1 N=58 Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
Allergic Bronchopulmonary Aspergillosis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAE) — 0; 3; 2; 2 participants
Phase 1 N=33 Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)
Solid Neoplasms
Primary: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) as Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 by the…
Early Phase 1 N=18 I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers
Healthy Volunteers · Alzheimer Disease · Molecular Imaging
Primary: Determination of the Regional Density and Distribution of I2BS in Healthy Human Brain (1TCM Model) — 44.5; 39.3; 62.7; 38.6 mL/cm^3
Phase 4 N=204 Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
Acute Coronary Syndrome (ACS)
Primary: Mean Change From Baseline to Week 4 in P2Y12 Reaction Units During Period 1 — -18.2 P2Y12 reaction unit
N/A N=720 The MOTS (Medication Overuse Treatment Strategy) Trial
Migraine
Primary: Frequency of Moderate to Severe Headache Days — 9.3; 9.1 days
Phase 1 N=12 Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients
Prostate Cancer
Primary: Safety Assessed by Development of Adverse Events and Dose-limiting Toxicity to Determine Maximum Tolerated Dose — 3; 3; 6; 0 Participants
Phase 2 N=193 Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
Non-alcoholic Steatohepatitis (NASH)
Primary: Number of Participants With Adverse Events — 42; 41; 40; 42 Participants